REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset — Tatsuya Yamashita (2019) | RDL Network
REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
Richard S. Finn, Ann‐Lii Cheng, Kenji Ikeda, Masatoshi Kudo, Toshiyuki Tamai, Corina E. Dutcus, Steven Younger, Kwang–Hyub Han, Shukui Qin, Éric Raymond
T.R. Jeffry Evans, Masatoshi Kudo, Richard S. Finn, Kwang–Hyub Han, Ann‐Lii Cheng, Masafumi Ikeda, Silvija Kraljevic, Min Ren, Corina E. Dutcus, Fabio Piscaglia, Max W. Sung
Ann‐Lii Cheng, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean–Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Min Ren, Silvija Kraljevic, Toshiyuki Tamai, Masatoshi Kudo
Angel Alsina, Masatoshi Kudo, Arndt Vogel, Ann‐Lii Cheng, Won Young Tak, Baek‐Yeol Ryoo, T.R. Jeffry Evans, Carlos López, Bruno Daniele, Soamnauth Misir, Min Ren, Namiki Izumi, Shukui Qin, Richard S. Finn
Discussion(0)
No comments yet. Be the first to comment.